{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:14:48Z","timestamp":1791360888164,"version":"4.3.1"},"reference-count":41,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2021R1A2C2093617"],"award-info":[{"award-number":["NRF-2021R1A2C2093617"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>In the context of glaucoma, intraocular pressure (IOP) and age are recognized as the primary factors contributing to its onset and progression. However, significant reductions in IOP fail to completely halt its advancement. An emerging body of literature highlights the role of neuroinflammation in glaucoma. This study aimed to explore Bromfenac\u2019s anti-inflammatory properties in mitigating neuroinflammation associated with glaucoma using an ischemia\u2013reperfusion (IR) glaucoma model. Bromfenac\u2019s impact on microglia and astrocytes under pressure was assessed via Western blotting and an enzyme-linked immunosorbent assay. Immunohistochemical staining was used to evaluate glial activation and changes in inflammatory marker expression in the IR model. Bromfenac led to the downregulation of inflammatory markers, which were elevated in the conditions of elevated pressure, and necroptosis markers were downregulated in astrocytes. In the IR model, elevated levels of GFAP and Iba-1 indicated glial activation. Following Bromfenac administration, levels of iNOS, COX-2, and PGE2-R were reduced, suggesting a decrease in neuroinflammation. Furthermore, Bromfenac administration in the IR model resulted in the improved survival of retinal ganglion cells (RGCs) and preservation of retinal function, as demonstrated by immunohistochemical staining and electroretinography. In summary, Bromfenac proved effective in diminishing neuroinflammation and resulted in enhanced RGC survival.<\/jats:p>","DOI":"10.3390\/cells13121046","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T08:48:31Z","timestamp":1718614111000},"page":"1046","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Bromfenac on Reducing Neuroinflammation in an Ischemia\u2013Reperfusion Glaucoma Model"],"prefix":"10.3390","volume":"13","author":[{"given":"Si-Eun","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Kee","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-5332","authenticated-orcid":false,"given":"Hae-Young Lopilly","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1350-9462(98)00014-7","article-title":"Neuronal death in glaucoma","volume":"18","author":"Quigley","year":"1999","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/1673-5374.245465","article-title":"Neuroinflammation as a target for glaucoma therapy","volume":"14","author":"Adornetto","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.exer.2017.02.014","article-title":"Neuroinflammation in glaucoma: A new opportunity","volume":"157","author":"Williams","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jnr.24256","article-title":"Neuroinflammation and microglia in glaucoma: Time for a paradigm shift","volume":"97","author":"Wei","year":"2019","journal-title":"J. Neurosci. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.exer.2010.08.009","article-title":"Neuroprotection in glaucoma\u2014Is there a future role?","volume":"91","author":"Baltmr","year":"2010","journal-title":"Exp. Eye Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3760\/cma.j.issn.0366-6999.20123565","article-title":"Neuroprotection in glaucoma: Present and future","volume":"126","author":"Chen","year":"2013","journal-title":"Chin. Med. J."},{"key":"ref_7","first-page":"2109","article-title":"Current perspective of neuroprotection and glaucoma","volume":"9","author":"Tian","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/jnr.1104","article-title":"Activated microglia in the human glaucomatous optic nerve head","volume":"64","author":"Yuan","year":"2001","journal-title":"J. Neurosci. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cne.22516","article-title":"Early microglia activation in a mouse model of chronic glaucoma","volume":"519","author":"Bosco","year":"2011","journal-title":"J. Comp. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00441-013-1666-y","article-title":"The role of M\u00fcller glia and microglia in glaucoma","volume":"353","author":"Seitz","year":"2013","journal-title":"Cell Tissue Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Oh, S.-E., Kim, J.-H., Shin, H.-J., Kim, S.-A., Park, C.-K., and Park, H.-Y.L. (2023). Angiotensin II-Related Activation of Scleral Fibroblasts and Their Role on Retinal Ganglion Cell Death in Glaucoma. Pharmaceuticals, 16.","DOI":"10.21203\/rs.3.rs-2470060\/v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41419-022-04762-4","article-title":"Angiotensin II related glial cell activation and necroptosis of retinal ganglion cells after systemic hypotension in glaucoma","volume":"13","author":"Jeon","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.2147\/OPTH.S86971","article-title":"Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: A review","volume":"10","author":"Sheppard","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1517\/14656560903188425","article-title":"Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent","volume":"10","author":"Jones","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_15","unstructured":"Bakalyan, G., Deshmukh, H., and Patterson, H. (2006, January 17\u201322). Concentrations of radioactivity in ocular tissues after a single topical dose of C-bromfenac ophthalmic solution. Proceedings of the American Society of Cataract and Refractive Surgery (ASCRS) Meeting, San Francisco, CA, USA."},{"key":"ref_16","unstructured":"McNamara, T., Baklayan, G., and Deshmukh, H. (May, January 30). Concentrations of radioactivity in ocular tissues after a single 0.09% topical dose of C-bromfenac ophthalmic solution. Proceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Ft. Lauderdale, FL, USA."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejphar.2016.03.064","article-title":"Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation","volume":"787","author":"Russo","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s10792-020-01515-0","article-title":"The photopic negative response (PhNR): Measurement approaches and utility in glaucoma","volume":"40","author":"Prencipe","year":"2020","journal-title":"Int. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1167\/iovs.14-14515","article-title":"Nitric oxide (NO): An emerging target for the treatment of glaucoma","volume":"55","author":"Cavet","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/ars.2006.8.929","article-title":"Regulation of inducible nitric oxide synthase gene in glial cells","volume":"8","author":"Saha","year":"2006","journal-title":"Antioxid. Redox Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9438","DOI":"10.1167\/iovs.11-7839","article-title":"eNOS, a pressure-dependent regulator of intraocular pressure","volume":"52","author":"Stamer","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1167\/iovs.12-11491","article-title":"Effect of nitric oxide on anterior segment physiology in monkeys","volume":"54","author":"Heyne","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1120672121998913","article-title":"Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma","volume":"32","author":"Mehta","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40265-018-0914-6","article-title":"Latanoprostene bunod ophthalmic solution 0.024%: A review in open-angle glaucoma and ocular hypertension","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0039-6257(97)84043-X","article-title":"Nitric oxide in the eye: Multifaceted roles and diverse outcomes","volume":"42","author":"Becquet","year":"1997","journal-title":"Surv. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archopht.1997.01100150499009","article-title":"Nitric oxide synthase in the human glaucomatous optic nerve head","volume":"115","author":"Neufeld","year":"1997","journal-title":"Arch. Ophthalmol."},{"key":"ref_28","first-page":"2884","article-title":"Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure","volume":"40","author":"Shareef","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1006\/exer.2002.2042","article-title":"Loss of retinal ganglion cells following retinal ischemia: The role of inducible nitric oxide synthase","volume":"75","author":"Neufeld","year":"2002","journal-title":"Exp. Eye Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00061198-200206000-00010","article-title":"A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma","volume":"11","author":"Neufeld","year":"2002","journal-title":"J. Glaucoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/13816810.2016.1164193","article-title":"Prostaglandins in the eye: Function, expression, and roles in glaucoma","volume":"38","author":"Doucette","year":"2017","journal-title":"Ophthalmic Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/OPTH.S340386","article-title":"Efficacy and patient tolerability of omidenepag isopropyl in the treatment of glaucoma and ocular hypertension","volume":"16","author":"Matsuo","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neuro.2011.02.004","article-title":"Prostanoid signaling: Dual role for prostaglandin E2 in neurotoxicity","volume":"32","author":"Milatovic","year":"2011","journal-title":"Neurotoxicology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/jnen\/63.9.901","article-title":"Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases","volume":"63","author":"Minghetti","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","article-title":"Necroptosis: The release of damage-associated molecular patterns and its physiological relevance","volume":"38","author":"Kaczmarek","year":"2013","journal-title":"Immunity"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Polansky, J., and Weinreb, R. (1984). Anti-inflammatory agents: Steroids as anti-inflammatory agents. Pharmacology of the Eye, Springer.","DOI":"10.1007\/978-3-642-69222-2_11"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archopht.1996.01100140208016","article-title":"Corticosteroid therapy of eye disease: Fifty years later","volume":"114","author":"Raizman","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jop.1987.3.43","article-title":"Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing","volume":"3","author":"Waterbury","year":"1987","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000068563","article-title":"Topical nonsteroidal anti-inflammatory therapy in ophthalmology","volume":"217","author":"Schalnus","year":"2003","journal-title":"Ophthalmologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/OPTH.S4806","article-title":"Management of ocular inflammation and pain following cataract surgery: Focus on bromfenac ophthalmic solution","volume":"6","author":"Cho","year":"2009","journal-title":"Clin. Ophthalmol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/12\/1046\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:59:57Z","timestamp":1760108397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/12\/1046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cells13121046"],"URL":"https:\/\/doi.org\/10.3390\/cells13121046","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]}}}